Literature DB >> 33932199

Risk of Postpartum Flare Hospitalizations in Patients with Inflammatory Bowel Disease Persists After Six Months.

Timothy Wen1, Adam S Faye2, Kate E Lee3, Alexander M Friedman1, Jason D Wright1, Benjamin Lebwohl4, Jean-Frederic Colombel5.   

Abstract

BACKGROUND: Although patients with IBD are at higher risk for flares during the postpartum period, little is known about the risk factors, timeline, and healthcare-associated costs of a readmission flare. AIMS: To ascertain the timeline in which patients are hospitalized for postpartum inflammatory bowel disease (IBD) flares, and the associated risk factors.
METHODS: This is a nationwide retrospective cohort study of 7054 patients with IBD who delivered between 2010-2014 obtained from the National Readmissions Database. The presence of IBD was defined using previously validated International Classification of Diseases codes, and univariable and multivariable regression models were performed to assess risk factors associated with a postpartum flare hospitalization over the nine-month observation period.
RESULTS: A total of 353 (5.0%) patients were hospitalized for a postpartum IBD flare, with approximately one-third (30.0%) readmitted after 6 months. On multivariable analysis, having Crohn's disease (aRR 1.47, 95%CI 1.16-1.88), Medicare insurance (aRR 3.30, 95%CI 2.16-5.02), and ≥ 2 comorbidities (aRR 1.34, 95%CI 1.03-1.74) were independently associated with a higher risk of an IBD flare hospitalization. Compared to patients aged 25-29, those 20-24 were at higher risk for an IBD flare readmission (aRR 1.58, 95%CI 1.17-2.13), whereas patients aged 35-39 years were at lower risk (aRR 0.63, 95%CI 0.43-0.92).
CONCLUSIONS: Among patients with IBD, Crohn's disease, Medicare insurance, multiple comorbidities, and younger age were independent risk factors for a postpartum IBD flare hospitalization. As approximately one-third of these readmissions occurred after 6 months, it is imperative to ensure adequate follow-up and treatment for postpartum IBD patients, particularly in the extended postpartum period.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Flare; IBD; Postpartum; Readmissions

Mesh:

Year:  2021        PMID: 33932199     DOI: 10.1007/s10620-021-06999-z

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.487


  34 in total

1.  Genetics and phenotypes in inflammatory bowel disease.

Authors:  Joana Torres; Jean-Frédéric Colombel
Journal:  Lancet       Date:  2015-10-18       Impact factor: 79.321

2.  The epidemiology of inflammatory bowel disease in Canada: a population-based study.

Authors:  Charles N Bernstein; Andre Wajda; Lawrence W Svenson; Adrian MacKenzie; Mieke Koehoorn; Maureen Jackson; Richard Fedorak; David Israel; James F Blanchard
Journal:  Am J Gastroenterol       Date:  2006-07       Impact factor: 10.864

3.  Continuing education module: postpartum maternal health care in the United States: a critical review.

Authors:  Ching-Yu Cheng; Eileen R Fowles; Lorraine O Walker
Journal:  J Perinat Educ       Date:  2006

4.  The Effect of Disease Activity on Birth Outcomes in a Nationwide Cohort of Women with Moderate to Severe Inflammatory Bowel Disease.

Authors:  Heidi Kammerlander; Jan Nielsen; Jens Kjeldsen; Torben Knudsen; Sonia Friedman; Bente Nørgård
Journal:  Inflamm Bowel Dis       Date:  2017-06       Impact factor: 5.325

Review 5.  Ulcerative colitis.

Authors:  Ryan Ungaro; Saurabh Mehandru; Patrick B Allen; Laurent Peyrin-Biroulet; Jean-Frédéric Colombel
Journal:  Lancet       Date:  2016-12-01       Impact factor: 79.321

Review 6.  My treatment approach to management of the pregnant patient with inflammatory bowel disease.

Authors:  Susie W Ng; Uma Mahadevan
Journal:  Mayo Clin Proc       Date:  2014-03       Impact factor: 7.616

7.  Inflammatory bowel disease and pregnancy: lack of knowledge is associated with negative views.

Authors:  Christian P Selinger; Jayne Eaden; Warwick Selby; D Brian Jones; Peter Katelaris; Grace Chapman; Charles McDondald; John McLaughlin; Rupert W L Leong; Simon Lal
Journal:  J Crohns Colitis       Date:  2012-10-02       Impact factor: 9.071

8.  The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States.

Authors:  Michael D Kappelman; Sheryl L Rifas-Shiman; Ken Kleinman; Dan Ollendorf; Athos Bousvaros; Richard J Grand; Jonathan A Finkelstein
Journal:  Clin Gastroenterol Hepatol       Date:  2007-09-29       Impact factor: 11.382

Review 9.  Review article: the management of Crohn's disease and ulcerative colitis during pregnancy and lactation.

Authors:  H Schulze; P Esters; A Dignass
Journal:  Aliment Pharmacol Ther       Date:  2014-09-09       Impact factor: 8.171

Review 10.  Venous thromboembolism in inflammatory bowel disease.

Authors:  Kimberly Cheng; Adam S Faye
Journal:  World J Gastroenterol       Date:  2020-03-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.